GM-CSF-producing CD4 cells have a distinct transcriptional profile, which includes expression of GPR65. Our data provide a strong scientific rationale for clinical trials targeting GM-CSF in spondyloarthritis and additionally identify further targets including GPR65 involved in this likely ‘pathogenic’ module. The gene discussed is CSF2; the disease is spondyloarthropathy.